第一届肿瘤转化医学-朱景德.pptVIP

The new Bladder cancer cases (both sexes) 1.Cyctoscopy(金标准) Invasive Subjective Misdiagnosis: 10-40% 2.Urine cytology Low sensitivity Need: 1, about 20% tested: bladder cancer; 2, more than 5 times tests per patient http://globocan.iarc.fr In confidence * The first attempt: DNA analysis in urine sediment for bladder cancer detection A new set of DNA methylation biomarkers - from the methylomic profiling of two cases of the normal tissues and two bladder cancer cell lines Methylomic profiling technology 2, MBD affinity chromatography 1, Sonicated DNA/Adaptor (1) Sequencing A, Unbound (2) (3) (4) Elution Several thousands of the cancer state specific hyperrmethylated targets The diagnostic kit An informative set of 5 　 　 1 2 3 4 5 　 Bladder cancer (131) 65.6% 34.4% 51.1% 48.1% 67.2% 　 Non cancerous lesion (36) 0.00% 0.00% 11.11% 11.11% 11.11% Accumulated sensitivity 65.6% 71.0% 80.5% 88.5% 94.75 Accumulated specificity 100% 100% 88.9% 86.1% 83.3% 71% 94.75% 100% 早期膀胱癌可以捡出率 (11/131 cases ) * 文章和专利 in preparation! 术前 术后 A sensitive/timely assay for the quality of the surgery; DNA甲基化 的频率 1, Sample extraction Kit 3, The multiplex real time PCR 2, Non-bisulfite methylation analysis SFDA approval 1, Cancer diagnosis 2, Physical Check-up; 3, Screening for non-symptom sufferers Clinical Assessment Set 1(3)： 靶点1， （FAM）， 2，（ROX）， 3，Cyc5， ＋ Internal Control: HEX; Set 2(2)： 靶点4， （FAM）， 5，（ROX）， ＋ Internal Control: HEX We are here !!! * Set 1 Set 2 Challenges: 1, Sensitivity and Specificity; 2, The desirable range for quantification. 　 　 　 　 　 　 　 　 1 2 3 4 5 6 Cancer sample （134） 41.0% 40.3% 33.6% 50.8% 24.6% 57.5% Normal control（22） 0.0% 0.0% 0.0% 4.5% 4.5% 4.5% Accumulated sensitivity 41.0% 66.4% 74.6% 85.8% 89.6% 94.8% Accumulated specificity 100.0% 100.0% 100.0% 95.5% 90.9% 86.4% 　 　 　 　 　 　 　 74.6% //100% 94.8% //90.9%% * Non-small Cell Lung Cancer// Plasma DNA methylation In confidence * * CTC: Circulating Tumor Cells Dissemination of